Biopharmaceutical company Intra-Cellular Therapies Inc (Nasdaq:ITCI) on Tuesday announced positive topline results from a Phase 3 trial evaluating CAPLYTA (lumateperone) for the prevention of relapse in patients with schizophrenia.
The study demonstrated that lumateperone significantly delayed relapse compared to placebo. There were 18 relapses (16.4%) in the lumateperone group versus 44 relapses (38.6%) in the placebo group. Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo.
The treatment was generally safe and well-tolerated.
These positive results highlight the potential of CAPLYTA as a maintenance therapy for schizophrenia.
MicuRx completes Phase III trial for MRX-4 for injection in China
Renalys Pharma secures Orphan Drug Designation in Japan for sparsentan
Minghui Pharmaceutical reports phase III success for MH004 ointment in atopic dermatitis
CBC Group acquires UCB's mature neurology and allergy business in China
MGI Tech collaborates with Universidad de San Martin de Porres
Allink Biotherapeutics completes USD42m Series A financing round
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children